WSTAM
BIO icon

Wilbanks Smith & Thomas Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-61
Closed -$19K – 456
2018
Q3 		$19K Buy
+61
New +$18.9K ﹤0.01% 892

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's BIO Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2018, closing a stake of 61 shares — an estimated $19K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in BIO in Q3 2018 and held it in 1 quarter. The position peaked at $19K in Q3 2018. 328 funds tracked by Wall St. Rank hold BIO as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 61 Bio-Rad Laboratories Class A shares in Q4 2018, an estimated $19K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Bio-Rad Laboratories Class A position peaked at $19K in Q3 2018.
  • 328 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.